Form 4: Heron Therapeutics CEO Acquires Shares via RSU Vesting
Insider Transaction Report
Heron Therapeutics CEO Craig Collard acquired 13,797 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership.
Summary
- Craig Collard, CEO and Director of Heron Therapeutics, Inc. (HRTX), acquired 13,797 shares of common stock on October 19, 2025.
- This acquisition resulted from the vesting of restricted stock units (RSUs), where each RSU represents a contingent right to receive one share of common stock.
- Following this transaction, Mr. Collard directly beneficially owns 488,335 shares of common stock.
- He also continues to beneficially own 124,172 restricted stock units.
- The RSUs vest in 16 equal quarterly installments, starting one quarter after the grant date of January 19, 2024.
- A Power of Attorney, effective September 4, 2025, designates Kathryn Lester and Melissa Jarel to act on behalf of Craig Collard for SEC filings and related administrative tasks.
Sentiment
Score: 6
Explanation: The filing reports a routine, expected insider transaction (RSU vesting) which is generally a neutral to slightly positive event as it increases executive ownership and aligns interests, but does not indicate new strategic developments or financial performance.
Positives
- CEO Craig Collard's direct beneficial ownership of common stock increased by 13,797 shares, signaling continued alignment with shareholder interests.
- The vesting of restricted stock units represents a planned component of executive compensation.
Future Outlook
The filing does not provide specific forward-looking statements or guidance beyond the scheduled vesting of restricted stock units.
Industry Context
This Form 4 filing details a routine insider transaction related to executive compensation, which is a standard practice across publicly traded companies in the biotechnology and pharmaceutical sectors. It does not provide information to assess broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Attorney-in-Fact | Craig Collard granted a Power of Attorney to Kathryn Lester and Melissa Jarel to handle SEC filings (Forms 3, 4, 5, 13D, 13G, 144) and EDGAR system administration on his behalf. | 09/04/2025 | This is a standard administrative measure to facilitate timely and accurate SEC compliance for the reporting person, ensuring efficient management of insider transaction disclosures. |
Related Party Transactions
- The vesting of restricted stock units and subsequent acquisition of common stock by CEO Craig Collard from Heron Therapeutics, Inc. constitutes a related party transaction as part of his compensation package.
Stakeholder Impact
- Shareholders: Increased direct ownership by the CEO may be viewed positively as it aligns management's interests with those of shareholders.
- Employees: The RSU vesting is part of an executive compensation structure, which can influence overall compensation philosophy within the company.
Next Steps
- Continued vesting of the remaining 124,172 restricted stock units in 16 equal quarterly installments from the grant date of January 19, 2024.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Grant date for restricted stock units, with vesting beginning one quarter later. |
| 09/04/2025 | Effective date of the Power of Attorney granted by Craig Collard. |
| 10/19/2025 | Date of transaction for the acquisition of common stock via RSU vesting. |
| 10/21/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdThe filing details a routine, expected insider transaction (RSU vesting) by the CEO, which does not provide new material information regarding the company's operational performance, strategic direction, or financial health. While increased insider ownership is generally positive, this specific event is a pre-scheduled compensation component and does not warrant a change in investment recommendation based solely on this filing.
Keywords
Heron Therapeutics, HRTX, Craig Collard, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Ownership, Director, CEO, Power of Attorney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.